Le Lézard
Classified in: Health, Science and technology

Radiance Biopharma to Present at LSX World Congress 2024


Presentation on Monday, April 29th at 11:15 AM (London Time)

BOSTON MA / ACCESSWIRE / April 26, 2024 / Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that Robert Brooks, JD, Chief Executive Officer of Radiance will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 11:15AM (GMT+1) in London, England.

In addition to the presentation, Mr. Brooks will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, visit https://informaconnect.com/lsx-world-congress/ A replay of the presentation will be made available on the Company's website, www.Radiancebiopharma.com, following the conclusion of the conference.

About LSX World Congress 2024

The 10th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core. The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes.

About Radiance Biopharma, Inc.

Radiance Biopharma Inc. is a biotechnology company focused on the discovery, development and commercialization of Antibody Drug Conjugates and next generation Bispecfic Antibody Drug Conjugates. Radiance's lead asset RB-201 is a 'First in Class' anti-HER2/TROP2 Bispecfic Antibody Drug Conjugate, that has demonstrated significant efficacy in animal studies in various solid tumors. Radiance is planning to conduct a Phase 1 Clinical Trial in early 2025.

For more information, please visit www.Radiancebiopharma.com.

Investor Relations Contact
Radiance Biopharma
[email protected]
Tel: (617) 621-7143

SOURCE: Radiance Biopharma



View the original press release on accesswire.com


These press releases may also interest you

at 18:55
ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
ZYUS Life Sciences Corporation ("ZYUS" or the "Company") is pleased to announce that Brent Zettl, President and CEO of ZYUS, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place on May...

at 18:42
George Weston Limited Announces Election of Directors
George Weston Limited ("Weston" or the "Company") today announced that all of the nominee directors listed in its management proxy circular dated March 19, 2024, were elected as directors of the Company. The vote was conducted at the Company's...

at 18:41
Family Source Consultants' New Modern Client-Focused Office for Surrogacy Agency Set to Revolutionize Family-Building Services
Family Source Consultants, LLC, a leading provider of surrogacy, egg donation, and all third-party reproduction services, is excited to announce the grand opening of its new state-of-the-art office dedicated to enhancing the journeys of intended...

at 18:15
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024....

at 18:00
Denny's Canada invites guests to enjoy a sweet treat in support of women's health
In recognition of Mother's Day on May 12th, Denny's Canada is delighted to announce that they have partnered with Women's Health Collective Canada (WHCC) to host a special fundraiser. From May 7th to 12th, in participating stores across Canada, $2...

at 17:41
Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...

More news about Health...


News published on and distributed by: